TRVN - トレベナ (Trevena Inc.) トレベナ

 TRVNのチャート


 TRVNの企業情報

symbol TRVN
会社名 Trevena Inc (トレベナ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 トレベナ(Trevena Inc.)は多様な治療法の開発に従事するバイオ医薬品会社である。同社は静脈内(IV)投与が好ましい中等度から重度の急性疼痛の管理のためのu-受容体Gタンパク質経路選択モジュレーター(u-GPS)であるOLINVOを開発中である。同社は病院と外来手術センターなどの急性ケア施設で使用するために米国で商業化することを主とする。また、片頭痛の治療のための非麻薬性機構を有する化合物として、o-受容体を標的とするGタンパク質偏向リガンドであるTRV250を開発している。TRV250はまた、他の中枢神経系(CNS)適応症に使用される。同社は英国でTRV250の第I相試験開始に焦点を当てる。そのABLE製品プラットフォームは、多様な医薬品特性を持つユニークなGタンパク質共役型受容体(GPCR)標的化リガンドを同定するために使用される生物学的情報、インビトロアッセイ、ノウハウおよび専門知識のコレクションである。   トレベナは米国のバイオ医薬品会社で、Gタンパク質共役受容体(GPCR)をタ―ゲットにした治療薬の開発に焦点を置く。中度から重度の疼痛に対する点滴剤TRV130と経口剤TRV734のほか、急性心疾患の点滴剤TRV027治験を行う。また、難治性片頭痛の経口剤TRV250の開発を行う。   Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with CNS disorders. The Company has one approved product in the United States, OLINVYK™ (oliceridine) injection, indicated inadults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company also has four novel and differentiated investigational drug candidates: TRV250 for the acute treatment of migraine, TRV734 for maintenance treatment of opioid use disorder, and TRV027 for acute lung injury / abnormal blood clotting in COVID-19 patients. The Company has also identified TRV045, a novel S1P receptor modulator that may offer a new approach to treating a variety of CNS disorders.
本社所在地 955 Chesterbrook Boulevard Suite 200 Chesterbrook PA 19087 USA
代表者氏名 Leon O. Moulder レオン・O・モルダー
代表者役職名 Independent Chairman of the Board
電話番号 +1 610-354-8840
設立年月日 39387
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数
url www.trevenainc.com
nasdaq_url https://www.nasdaq.com/symbol/trvn
adr_tso
EBITDA EBITDA(百万ドル) -45.30600
終値(lastsale) 2.98
時価総額(marketcap) 226725194.4
時価総額 時価総額(百万ドル) 72.04992
売上高 売上高(百万ドル) 2.50000
企業価値(EV) 企業価値(EV)(百万ドル) 31.94392
当期純利益 当期純利益(百万ドル) -49.04400
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Trevena Inc revenues increased from $0K to $2.5M. Net loss decreased 55% to $18.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and development - Balancing val decrease of 70% to $9M (expense) Miscellaneous income increase from $628K to $1.4M (income).

 TRVNのテクニカル分析


 TRVNのニュース

   Is Trevena Inc. (NASDAQ: TRVN) Hit More of the Losses Given A -494.59% Dip From High?  2022/06/03 15:00:00 Marketing Sentinel
During the last session, Trevena Inc. (NASDAQ:TRVN)’s traded shares were 3.64 million, with the beta value of the company hitting 2.47. At the end of the trading day, the stock’s price was $0.37, reflecting an intraday gain of 10.94% or $0.04. The 52-week high for the TRVN share is $2.20, that puts it down -494.59 … Is Trevena Inc. (NASDAQ: TRVN) Hit More of the Losses Given A -494.59% Dip From High? Read More »
   Trevena Inc. (NASDAQ:TRVN) 16.84% Up Over The Last Seven Days. Can The Stock Hit Well Above $0.0354?  2022/05/20 13:00:00 Marketing Sentinel
In last trading session, Trevena Inc. (NASDAQ:TRVN) saw 1.28 million shares changing hands with its beta currently measuring 2.51. Company’s recent per share price level of $0.25 trading at -$0.02 or -9.97% at ring of the bell on the day assigns it a market valuation of $42.10M. That closing price of TRVN’s stock is at … Trevena Inc. (NASDAQ:TRVN) 16.84% Up Over The Last Seven Days. Can The Stock Hit Well Above $0.0354? Read More »
   Trevena Inc. (NASDAQ: TRVN) Is On The Rise  2022/05/17 13:00:00 Stocks Register
Trevena Inc. (NASDAQ:TRVN) traded at $0.30 at close of the session on Monday, 05/16/22, made an upward move of 49.16% on its previous day’s price. Looking at the stock we see that its previous close was $0.20 and the beta (5Y monthly) reads 2.27 with the day’s price range being $0.2056 – $0.36. In terms … Trevena Inc. (NASDAQ: TRVN) Is On The Rise Read More »
   Bears Are Back On The Defensive As Trevena Inc. (TRVN) tumbled -3.43%  2022/05/16 14:00:00 Marketing Sentinel
Trevena Inc. (NASDAQ:TRVN) has a beta value of 2.51 and has seen 1.66 million shares traded in the last trading session. The company, currently valued at $34.80M, closed the last trade at $0.20 per share which meant it lost -$0.01 on the day or -3.43% during that session. The TRVN stock price is -1000.0% off … Bears Are Back On The Defensive As Trevena Inc. (TRVN) tumbled -3.43% Read More »
   Trevena, Inc. (TRVN) CEO Carrie Bourdow on Q1 2022 Results - Earnings Call Transcript  2022/05/13 19:19:07 Seeking Alpha
Trevena, Inc. (NASDAQ:NASDAQ:TRVN) Q1 2022 Earnings Conference Call May 11, 2022 08:00 AM ET Company Participants Barry Shin - Senior Vice President & Chief Financial Officer Carrie…
   As The Stock Falls By -38.20% Year-To-Date, Trevena Inc. (NASDAQ: TRVN)’S Stock Continues To Progress In 2022  2022/04/23 19:00:00 Marketing Sentinel
During the last session, Trevena Inc. (NASDAQ:TRVN)’s traded shares were 0.7 million, with the beta value of the company hitting 2.32. At the end of the trading day, the stock’s price was $0.36, reflecting an intraday loss of -4.28% or -$0.02. The 52-week high for the TRVN share is $2.20, that puts it down -511.11 … As The Stock Falls By -38.20% Year-To-Date, Trevena Inc. (NASDAQ: TRVN)’S Stock Continues To Progress In 2022 Read More »
   Trevena reports data on effect of opioid drug Olinvyk in respiratory function in elderly  2022/04/20 12:05:26 Seeking Alpha
Trevena (TRVN) reported data from a study evaluating opioid drug Olinvyk (oliceridine) injection versus morphine for managing acute pain in elderly/overweight.The company said the…
   Trevena Announces Results from Respiratory Physiology Study of Head-to-Head Comparison of OLINVYK and IV Morphine in Elderly/Overweight Subjects  2022/04/20 11:00:00 Wallstreet:Online
OLINVYK showed a statistically significant reduced impact on respiratory function compared to IV morphine, among elderly/overweight subjects Data replicate observations previously seen in a comparative study of respiratory physiology in younger subjects with OLINVYK and IV morphine CHESTERBROOK, Pa., April 20, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company
   Trevena Announces Receipt of First $15 million Tranche in Connection with its $40 million ex-US Royalty-Based Financing with R-Bridge Healthcare Fund  2022/04/18 11:00:00 Wallstreet:Online
CHESTERBROOK, Pa., April 18, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced receipt of the first $15 million tranche from its royalty-based financing agreement with an affiliate of R-Bridge Healthcare Fund (the R-Bridge
   OLINVYK data selected as President’s Choice abstract at Annual Regional Anesthesiology and Acute Pain Medicine Meeting and Featured at American Burn Association Annual Meeting  2022/04/13 20:05:00 Wallstreet:Online
CHESTERBROOK, Pa., April 13, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced a summary of activities at recent medical meetings, relating to OLINVYK (oliceridine) injection, in several core therapeutic areas. Trevena attended
   Stock Runner: Trevena, Inc. (NASDAQ:TRVN), The Southern Company (NYSE:SO)  2021/12/24 04:31:36 Stock Equity
Trevena, Inc. (NASDAQ:TRVN) with the stream of 5.21% also noticed, India The Southern Company (NYSE:SO) encountered a rapid change of -0.17% in the last hour of Thursdays trading session. Trevena, The post Stock Runner: Trevena, Inc. (NASDAQ:TRVN), The Southern Company (NYSE:SO) appeared first on Stocks Equity .
   Flaming Stock: Trevena, Inc. (NASDAQ:TRVN), Mastercard Incorporated (NYSE:MA)  2021/12/20 00:44:28 Stock Equity
Trevena, Inc. (NASDAQ:TRVN) with the stream of 5.64% also noticed, India Mastercard Incorporated (NYSE:MA) encountered a rapid change of -1.02% in the last hour of Fridays trading session. Trevena, Inc. The post Flaming Stock: Trevena, Inc. (NASDAQ:TRVN), Mastercard Incorporated (NYSE:MA) appeared first on Stocks Equity .
   Zacks: Analysts Anticipate Trevena, Inc. (NASDAQ:TRVN) Will Announce Quarterly Sales of $670,000.00  2021/12/18 06:58:41 Dakota Financial News
Analysts expect Trevena, Inc. (NASDAQ:TRVN) to post sales of $670,000.00 for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Trevenas earnings, with estimates ranging from $280,000.00 to $1.06 million. Trevena posted sales of $70,000.00 in the same quarter last year, which suggests a positive year-over-year growth rate of 857.1%. []
   Trevena Offers An Enticing Risk-Reward At These Prices  2021/12/14 07:11:04 Seeking Alpha
   Trevena moves diabetic neuropathic pain candidate into phase 1  2021/12/13 12:53:43 Seeking Alpha

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 トレベナ TRVN Trevena Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)